KAKEN Pharmaceutical Acquires Aadi Subsidiary from Whitehawk Therapeutics for $100M
March 26, 2025
Whitehawk Therapeutics has completed the divestiture of Aadi Subsidiary, Inc. to KAKEN Pharmaceutical Co., Ltd. for $100 million in cash plus customary adjustments. KAKEN assumes ownership of the Aadi Bioscience name, trademarks and the FYARRO business; Whitehawk expects to use proceeds (together with a recent $100M PIPE) to fund its ADC pipeline and extend its cash runway into 2028.
- Buyers
- KAKEN Pharmaceutical Co., Ltd.
- Targets
- Aadi Subsidiary, Inc. (Aadi Bioscience)
- Sellers
- Whitehawk Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Supreme Group Acquires Kadiko
March 5, 2025
Marketing & Advertising
Supreme Group, a Trinity Hunt-backed platform for life sciences and healthcare marketing, has acquired Kadiko, a San Francisco–based digital-first brand strategy and creative agency. The add-on expands Supreme Group's AI-enhanced insights, digital and brand strategy capabilities to better serve healthcare and life sciences clients.
-
AbbVie Acquires Aliada Therapeutics for $1.4 Billion
December 11, 2024
Biotechnology
AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.
-
Advent International to Acquire Significant Stake in Suven Pharmaceuticals
December 26, 2022
Pharmaceuticals
Advent International has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family and will make an open offer for an additional 26% of public shares. Advent plans to evaluate a merger of its CDMO and API platform company, Cohance Lifesciences, with Suven to create a scaled end-to-end CDMO + merchant API powerhouse serving pharma and specialty chemical markets, subject to board and regulatory approvals.
-
Nihon Kohden Acquires 71.4% Stake in Ad‑Tech from ARCHIMED
November 26, 2024
Medical Devices
Nihon Kohden has acquired a 71.4% stake in NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, from ARCHIMED’s MED II fund, with ARCHIMED retaining a 28.6% minority stake and entering a joint venture with Nihon Kohden. The deal brings together Nihon Kohden’s EEG and monitoring platform with Ad‑Tech’s intracranial neuroelectrodes to strengthen epilepsy diagnostics and expand Ad‑Tech’s global reach across North America, Europe and Asia.
-
Bausch + Lomb Affiliate Acquires Whitecap Biosciences
January 13, 2025
Pharmaceuticals
An affiliate of Bausch + Lomb Corporation has acquired clinical-stage Whitecap Biosciences, LLC, which is developing two ophthalmic therapies (WB007 and WB006) for glaucoma and geographic atrophy. The deal strengthens Bausch + Lomb's clinical-stage pipeline — Whitecap completed a Phase 2 study for WB007 and plans additional trials for both indications.
-
AbbVie Acquires Mitokinin
October 5, 2023
Biotechnology
AbbVie has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a selective PINK1 activator for Parkinson's disease. AbbVie paid $110 million at closing with up to $545 million in additional milestone payments plus tiered royalties contingent on development and commercial milestones.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.